Trajan Completes Acquisition of SGE Business.
Trajan Scientific and Medical, “Trajan” has completed its acquisition of the Chromatography and Liquid Handling businesses of SGE Analytical Science, “SGE”. SGE was founded by Ern Dawes in Melbourne Australia in 1961 and has remained in the Dawes family for over 50 years. Its business, focussed on components and consumables used in scientific analysis has grown to around 300 staff worldwide with manufacturing operations in Ringwood Australia and subsidiary offices in the USA, Europe and Japan.
Dawes Holdings, the parent company of SGE, owned by Peter Dawes, will retain a range of assets, including the ETP Electron Multiplier business. Under the new ownership SGE will continue to work closely with ETP and provide global support and distribution services as is the case today.
Trajan, formed in 2011, acquired the pathology consumables business of Grale Scientific, (Victoria Australia) in October 2011.
“Trajan’s goal is to bring together a group of leading companies with a common focus in the areas of biological, environmental and food analysis. SGE is an ideal platform for Trajan, with a global footprint and a depth of capability and infrastructure, servicing the leading companies in analytical science’ said Stephen Tomisich CEO of Trajan.
Under the arrangement Trajan has acquired the manufacturing operations and site in Ringwood Australia, The SGE sites and operations in Europe and the USA and all shareholdings in the SGE subsidiaries located in Europe, the USA and Japan.
“We believe that we are in a unique position to serve the current and future needs of people working in the fields of scientific and medical analysis. Specifically we aim to invest in technologies that will deliver more sensitive, selective and more affordable analysis in biological, food and environmental applications. We also intend to fully embrace a global business model where we work with leading companies in the scientific industry to enhance their capacity to deliver solutions in these target areas.”
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.